Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease

Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18-60
SponsorMostafa Bahaa

About this trial

The inflammatory bowel diseases (IBD) are described as complex, recurrent inflammatory conditions which are manifested as Crohn's disease (CD) and ulcerative colitis (UC). The common symptoms of IBD include debilitating/severe diarrhea, abdominal pain, weight loss, and chronic fatigue; events that may culminate in life-threatening complications. The pathogenesis of IBD has been characterized as complex/multi-factorial that includes disruption of intestinal epithelial barrier with consequent translocation of commensal microbial products as the prime event that instigates severe immune responses and intestinal inflammation.

Eligibility criteria

Qualifiers

Age ≥ 18 years

Both male and female will be

Mild and moderate UC patients diagnosed and confirmed by endoscope

Disqualifiers

Breast feeding

Significant liver and kidney function abnormalities

Colorectal cancer patients

Patients with severe UC

Trial design

Treatments tested in this trial

  • Mesalamine
  • Dapagliflozin 10mg Tab

Treatment groups

50 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Mostafa Bahaa

Lead sponsor

Tanta University

Sponsor institution